Litigation Details for Pfizer Inc. v. Mylan Pharmaceuticals Inc. (J.P.M.L. 2019)

« Back to Dashboard

Pfizer Inc. v. Mylan Pharmaceuticals Inc. (J.P.M.L. 2019)

Docket		Date Filed	2019-04-29
Court	United States Judicial Panel on Multidistrict Litigation	Date Terminated
Cause		Assigned To	Irene M. Keeley
Jury Demand		Referred To
Patents	6,936,612; 7,208,489; 7,456,168
Link to Docket	External link to docket

Details for Pfizer Inc. v. Mylan Pharmaceuticals Inc. (J.P.M.L. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-29				External link to document
2019-04-29	1	Complaint (NOT for attorney use)	Exhibit A US Patent 6,936,612 B@, # 2 Exhibit B US Patent 7,208,489 B2, # 3 Exhibit C US Patent 7,456,168B2… to the expiration of U.S. Patent No. 6,936,612 ("the '612 patent"); … #: 2 U.S. Patent No. 7,208,489 ("the '489 patent"); and U.S. Patent No. 7,456,168 …;168 patent"). These three patents are referred to collectively herein as "the patents-in-suit…x27;489 patent, and/or validity of the '489 patent. The '489 patent claims,	External link to document
2019-04-29	33		(B)(iii). 5 U.S. Patent Nos. 6,936,612, 7,208,489, and 7,456,168. Case… MULTIDISTRICT LITIGATION IN RE: PALBOCICLIB PATENT LITIGATION …, and 125 mg. All the actions are Hatch-Waxman4 patent infringement * Judge Ellen… Under the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98–417… “paragraph IV certification”—stating that the patents listed in the FDA’s Orange Book as covering the	External link to document